Trial Profile

A proof of concept trial of AQST-305 (octreotide sublingual formulation)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Octreotide (Primary)
Indications Acromegaly
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Aquestive Therapeutics

Most Recent Events

23 Nov 2018 New trial record
06 Nov 2018 According to an Aquestive Therapeutics media release, the company commenced this trial during the third quarter of 2018.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com